AU2021331087A1 - Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies - Google Patents

Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies Download PDF

Info

Publication number
AU2021331087A1
AU2021331087A1 AU2021331087A AU2021331087A AU2021331087A1 AU 2021331087 A1 AU2021331087 A1 AU 2021331087A1 AU 2021331087 A AU2021331087 A AU 2021331087A AU 2021331087 A AU2021331087 A AU 2021331087A AU 2021331087 A1 AU2021331087 A1 AU 2021331087A1
Authority
AU
Australia
Prior art keywords
antibody
dose
antigen
seq
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021331087A
Other languages
English (en)
Inventor
Urvi ARAS
Aberra Fura
Ihab GIRGIS
Karen PRICE
Nidhi SHARDA
Mary STRUTHERS
Ying Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2021331087A1 publication Critical patent/AU2021331087A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2021331087A 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies Pending AU2021331087A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070209P 2020-08-25 2020-08-25
US63/070,209 2020-08-25
PCT/US2021/047610 WO2022046942A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
AU2021331087A1 true AU2021331087A1 (en) 2023-04-20

Family

ID=77693641

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021331087A Pending AU2021331087A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies

Country Status (11)

Country Link
US (1) US20230331860A1 (https=)
EP (1) EP4204099A1 (https=)
JP (1) JP2023539736A (https=)
KR (1) KR20230054451A (https=)
CN (1) CN116322761A (https=)
AU (1) AU2021331087A1 (https=)
BR (1) BR112023002803A2 (https=)
CA (1) CA3190727A1 (https=)
IL (1) IL300765A (https=)
MX (1) MX2023002093A (https=)
WO (1) WO2022046942A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018361743A1 (en) * 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Also Published As

Publication number Publication date
CN116322761A (zh) 2023-06-23
MX2023002093A (es) 2023-03-15
JP2023539736A (ja) 2023-09-19
WO2022046942A1 (en) 2022-03-03
BR112023002803A2 (pt) 2023-03-14
IL300765A (en) 2023-04-01
CA3190727A1 (en) 2022-03-03
EP4204099A1 (en) 2023-07-05
US20230331860A1 (en) 2023-10-19
KR20230054451A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
US12409223B2 (en) Antagonistic CD40 monoclonal antibodies and uses thereof
JP7257335B2 (ja) アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用
CN103946240B (zh) 对人ox40具有特异性的抗体分子
EP2583980A1 (en) Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
AU2018271915B2 (en) Therapeutic anti-CD40 ligand antibodies
EP4095158A1 (en) Pharmaceutical composition containing anti-btla antibody and use thereof
JP2023531493A (ja) Ｉｌ－１０突然変異タンパク質及びその融合タンパク質
JP7797622B2 (ja) ヒトインターロイキン－４受容体アルファ抗体
AU2021331087A1 (en) Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies
EA052892B1 (ru) Антитела к альфа-рецептору интерлейкина-4 человека
JP2025124594A (ja) 抗ｉｌ２７ｒ抗体およびその使用の方法
CN121443309A (zh) 多发性骨髓瘤的治疗
EA051986B1 (ru) Антигенсвязывающий белок и слитый белок, его содержащий